GLP-1 therapy and lean mass: what the trials actually measured
A share of the weight lost on GLP-1 medicines is lean mass. What the published numbers say, what they do not, and what preserves muscle during weight loss in general.
Three caveats matter before drawing any conclusion from those percentages.
- These are separate pooled estimates from heterogeneous studies, with wide heterogeneity (one analysis reported I2 = 98%), not a single head-to-head comparison.
- Within that same review, lifestyle intervention alone was associated with 26.2% (p = 0.42, not statistically different from the incretin estimates) and lifestyle plus resistance training with 17.5%. These come from different study populations and must not be read as a direct comparison between drugs and training.
- A separate analysis in Annals of Internal Medicine reported a median of 28.3% of weight lost from muscle-based measures (IQR 15.9 to 39.9) within the incretin groups, across agents and measurement methods; the lifestyle and placebo groups were analysed separately in that paper.
A further meta-analysis found that absolute lean mass fell by about 1.74 kg, but lean mass as a share of body weight rose by about 1.81 percentage points, so people ended the studies relatively leaner. (How DXA lean mass relates to muscle tissue needs full-text verification; this article makes no imaging claim.)
| Measure | Figure | Source |
|---|---|---|
| Share of weight lost as lean mass, semaglutide | 35.2% (95% CI 31.5 to 38.9) | Systematic review, DOM 2026 |
| Share of weight lost as lean mass, tirzepatide | 25.4% | Systematic review, DOM 2026 |
| Share of weight lost as lean mass, liraglutide | 26.8% | Systematic review, DOM 2026 |
| Lifestyle intervention alone | 26.2% (p = 0.42) | Same review, separate populations |
| Lifestyle plus resistance training | 17.5% | Same review, separate populations |
| Median share from muscle-based measures, incretin groups | 28.3% (IQR 15.9 to 39.9) | Annals of Internal Medicine 2026 |
| Absolute lean mass change | about minus 1.74 kg | Meta-analysis, Int J Obes 2026 |
| Lean mass as share of body weight | up about 1.81 points | Same meta-analysis |
What the supporting evidence covers
In the general adult and older-adult populations those trials studied, resistance training and adequate protein intake are both evidence-backed strategies associated with preserving lean mass during weight loss.
Morton and colleagues (British Journal of Sports Medicine, 2018, 49 randomised trials) found protein plus resistance training added about 0.30 kg of fat-free mass, with little additional benefit above about 1.6 g of protein per kg per day. Kim and colleagues (Nutrition Reviews, 2016) found adults over 50 on calorie restriction kept more lean mass at higher protein intakes.
Neither source studied GLP-1 users or whey specifically, so evidence in GLP-1 users is still emerging, and neither establishes a hierarchy between the two strategies. This article carries no whey-specific or convenience claim; product questions belong on the product pages with their label sourcing.
What the advisory highlights
The joint advisory from ACLM, ASN, OMA and TOS identifies nutritional priorities during GLP-1 therapy for obesity and recommends resistance training and appropriate dietary support to help preserve muscle and bone mass.
It does not give a protein gram figure or a full nutrient list in its abstract, so no number is quoted here; the full text would be needed before any numeric claim.
Who should be careful
Older adults: per Morton and colleagues, the protein-plus-training effect on fat-free mass shrinks with age. Readers with medical questions should consult a qualified clinician before changing diet, exercise or medicines. Nothing here advises starting or stopping a prescribed medicine. This is not medical advice.
Disclosure
Everstack sells a whey protein add-on and a multivitamin. No structure-function claim about either product appears in this article, because no substantiation for a product claim sits in the sources cited here; label-compliant claims live on the product pages only.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Not ready to buy yet?
A short email when there is something worth saying: the evidence we have graded, label changes, and new batches.
Sources
- Lean mass changes with incretin therapy versus lifestyle intervention: systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab, 2026. doi.org/10.1111/dom.70666
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis. Int J Obes, 2026. doi.org/10.1038/s41366-026-02118-y
- Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr, 2025. doi.org/10.1016/j.ajcnut.2025.04.023
- Effect of incretin-based and nonpharmacologic weight loss on body composition. Ann Intern Med, 2026. doi.org/10.7326/ANNALS-25-00478
- Morton et al., Br J Sports Med 2018. doi.org/10.1136/bjsports-2017-097608
- Kim et al., Nutr Rev 2016. doi.org/10.1093/nutrit/nuv065
- STEP 1, NEJM 2021. doi.org/10.1056/NEJMoa2032183
- SURMOUNT-1, NEJM 2022. doi.org/10.1056/NEJMoa2206038